# About Script Wolverine: An Editorial Listing of the BPC-157 TB-500 Record

> About Script Wolverine — an independent editorial project that files and cites the published BPC-157 TB-500 research record. Not a clinic, not a pharmacy, not a vendor.

An independent editorial project that reads the published literature on the Wolverine blend and files it, finding by finding, with the source attached.

## What this site is

Script Wolverine is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide Wolverine blend. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is built as a curated listing. Each constituent finding, dosing parameter, and regulatory mark is filed as its own entry — with a tag for which peptide it belongs to, an evidence-tier status, and the citation attached — the way a property portal files a listing with a photo, a status, and a record. The point of that structure is honesty at a glance: a reader sees immediately whether a claim rests on confirmed preclinical evidence, on a human-data gap, or on the combination's complete absence of controlled trials.

## Why "Script," and what it does not mean

The "script" in the name is editorial framing — a position this publisher occupies relative to the prescription-and-access landscape, where the regulatory status of unapproved peptides is the central question. It is not a claim that this site writes prescriptions, fills them, or arranges access. We do not offer treatment, consultation, or prescription services, and the /legal-status page is general information about the regulatory landscape, not medical or legal advice.

What we do offer is a careful reading. We foreground the things the marketing tends to bury: that most BPC-157 and TB-500 evidence is rodent and single-compound, that the blend itself has never been tested in a controlled trial, that the "TB-500" most efficacy data describe is actually full-length Thymosin Beta-4, and that both constituents currently sit in FDA 503A Category 2. The record is interesting enough that it does not need inflating.

## How the record is sourced

Every quantitative claim on this site maps to a numbered citation on the references page — peer-reviewed journals, recent systematic and narrative reviews, and FDA primary sources. Where the literature is thin or silent, we say so rather than filling the gap with extrapolation. When studies disagree, or when a finding comes from a single research group, we note it. The listing format makes those caveats first-class entries, not footnotes.

---

A curated property-portal listing of the BPC-157 TB-500 record — each constituent finding, dose parameter, and FDA 503A access mark filed as its own cited entry, with no clinic, pharmacy, or prescription behind the keyline.